Last Updated : May 8, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Corzyna | ranolazine | Stable angina pectoris, adults | Do not reimburse | Complete | ||
| Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
| Kineret | anakinra | Still's disease | Withdrawn | |||
| Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | ||
| Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete | ||
| Benlysta | Belimumab | Systemic lupus erythematosus | Do not list | Complete | ||
| Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete |
Last Updated : May 8, 2024